Biotest AG: Board of Management and Supervisory Board propose 82% dividend increase
Biotest AG / Dividend/Miscellaneous
Release of a Corporate-announcement, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Biotest AG: Board of Management and Supervisory Board propose 82% dividend
increase
- Planned dividend of EUR 0.24 per ordinary share and EUR 0.30 per
preference share
- Total distribution payment up from almost EUR 1.6 million to more than
EUR 2.8 million
- Contract of the Chairman of the Board, Professor Dr. Gregor Schulz,
extended by five years
Dreieich, 13 March 2007. The Board of Management and Supervisory Board of
Biotest AG are proposing a marked increase in the dividend to be paid to
shareholders for financial year 2006. The dividend is set to amount to EUR
0.24 per ordinary share, which is double that paid out for financial year
2005. The dividend per preference share is set to rise by two thirds from
EUR 0.18 to EUR 0.30. The effect of this is an increase in the total
distribution payment of 82% to EUR 2.8 million compared with the previous
year (almost EUR 1.6 million).
The increase will enable stakeholders to participate in the excellent
earnings development of Biotest. In its session yesterday, the Supervisory
Board adopted the consolidated financial statements of the Biotest Group
and confirmed the preliminary figures, which have already been announced.
Net profit for the year amounts to EUR 16.0 million, which represents a
57.3% increase on the figure for the previous year (EUR 10.2 million).
Earnings before interest and taxes rose by 24.1% to EUR 31.4 million and
earnings before taxes grew by almost 43.9% to EUR 21.6 million. At EUR
281.9 million, Group sales were 18.7% higher than in 2005 (EUR 237.6
million).
In addition, the Supervisory Board resolved to extend the contract of
Chairman of the Board of Management, Professor Dr. Gregor Schulz, by five
years. Professor Schulz took up his appointment as Chairman of the Board of
Management in 2003. Under his leadership, the company has adopted a new
strategic focus and advanced its progress towards becoming a global
pharmaceutical, diagnostic and biotherapeutic group.
About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulines, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutics segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and serology and microbiology systems which are
used, for example, in blood transfusions. Biotest has around 1,200
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Marion Wendorff, Telefon: +49 (0) 6103 801-520,
E-Mail: marion_wendorff@biotest.de
Telefax: +49 (0) 6103 801-7840
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
DGAP 13.03.2007
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstr. 5
63303 Dreieich Deutschland
Phone: +49 - 6103 / 801 - 0
Fax: +49 - 6103 / 801 - 150
E-mail: mail@biotest.de
www: www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
